Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy.
Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy.
复制标题
糖尿病心肌病的代谢和分子成像
DOI：
10.1161/circresaha.120.315899
复制
发表时间：
2020-05-22
影响因子：
20.1
通讯作者：
Gropler RJ
中科院分区：
文献类型：
--
作者：
Peterson LR;Gropler RJ
The term “diabetic cardiomyopathy” is defined as the presence of abnormalities in myocardial structure and function that occur in the absence of, or in addition to, well-established cardiovascular risk factors. A key contributor to this abnormal structural-functional relation is the complex interplay of myocardial metabolic remodeling, defined as the loss the flexibility in myocardial substrate metabolism and its downstream detrimental effects such as mitochondrial dysfunction, inflammation and fibrosis. In parallel with the growth in understanding of these biological underpinnings has been developmental advances in imaging tools such as positron emission tomography and magnetic resonance imaging and spectroscopy that permit the detection and in many cases quantification, of the processes that typifies the myocardial metabolic remodeling in diabetic cardiomyopathy. The imaging readouts can be obtained in both pre-clinical models of diabetes mellitus and diabetic patients facilitating the bi-directional movement of information between bench and bedside. Moreover, imaging biomarkers provided by these tools are now being used to enhance discovery and development of therapies designed to reduce the myocardial effects of diabetes mellitus through metabolic modulation. In this review the use of these imaging tools in the diabetic patient from a mechanistic, therapeutic effect and clinical management perspective will be discussed.
